1093403-33-8 | 4-Methyl-N-(2-(3-(morpholinomethyl)imidazo[2,1-b]thiazol-6-yl)phenyl)-2-(pyridin-3-yl)thiazole-5-carboxamide

Packsize	Purity	Availability	Price	Discounted Price
1mg	97%	in stock	$20.00	$14.00
5mg	97%	in stock	$43.00	$30.00
10mg	97%	in stock	$62.00	$44.00
50mg	97%	in stock	$143.00	$101.00
100mg	97%	in stock	$219.00	$153.00
250mg	97%	in stock	$356.00	$249.00
1g	97%	in stock	$1,070.00	$749.00

Description

• Catalog Number: AE11334
• Chemical Name: 4-Methyl-N-(2-(3-(morpholinomethyl)imidazo[2,1-b]thiazol-6-yl)phenyl)-2-(pyridin-3-yl)thiazole-5-carboxamide
• CAS Number: 1093403-33-8
• Molecular Formula: C26H24N6O2S2
• Molecular Weight: 516.6377599999998
• MDL Number: MFCD22572733
• SMILES: O=C(c1sc(nc1C)c1cccnc1)Nc1ccccc1c1cn2c(n1)scc2CN1CCOCC1

Computed Properties

• Complexity: 758
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 36
• Hydrogen Bond Acceptor Count: 8
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 6
• XLogP3: 4.2

Upstream Synthesis Route

4-Methyl-N-[2-[3-(4-morpholinylmethyl)imidazo[2,1-b]thiazol-6-yl]phenyl]-2-(3-pyridinyl)-5-thiazolecarboxamide is a versatile compound commonly used in chemical synthesis as a key building block for the preparation of novel pharmaceutical agents, agrochemicals, and fluorescent dyes. Its unique structure containing multiple functional groups allows for efficient derivatization and incorporation into diverse molecular frameworks. In organic synthesis, this compound serves as a valuable intermediate for the synthesis of potent bioactive molecules through various synthetic routes, enabling the development of new therapeutic agents and research tools.

Literature

• Assessing Colonic Exposure, Safety, and Clinical Activity of SRT2104, a Novel Oral SIRT1 Activator, in Patients with Mild to Moderate Ulcerative Colitis.

  Inflammatory bowel diseases 20160301

• A Randomized, Placebo-Controlled Study of SRT2104, a SIRT1 Activator, in Patients with Moderate to Severe Psoriasis.

  PloS one 20150101

• Sirtuin 1 activator SRT2104 protects Huntington's disease mice.

  Annals of clinical and translational neurology 20141201

• SRT2104 extends survival of male mice on a standard diet and preserves bone and muscle mass.

  Aging cell 20141001

• A phase II, randomized, placebo-controlled, double-blind, multi-dose study of SRT2104, a SIRT1 activator, in subjects with type 2 diabetes.

  British journal of clinical pharmacology 20140701